Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Homocysteine Lowering Trialists' Collaboration Correspondence to: Dr Robert
Clarke, Homocysteine Lowering Trialists' Collaboration, Clinical Trial
Service Unit, Radcliffe Infirmary, Oxford OX2 6HE
robert.clarke{at}ctsu.ox.ac.uk
Objective: To determine the size of reduction in
homocysteine concentrations produced by dietary supplementation with folic acid and with vitamins B-12 or B-6.
Design: Meta-analysis of randomised controlled trials
that assessed the effects of folic acid based supplements on blood
homocysteine concentrations. Multivariate regression analysis was used
to determine the effects on homocysteine concentrations of different
doses of folic acid and of the addition of vitamin B-12 or B-6.
Subjects: Individual data on 1114 people included in
12 trials.
Findings: The proportional and absolute reductions in
blood homocysteine produced by folic acid supplements were greater at
higher pretreatment blood homocysteine concentrations (P<0.001) and at
lower pretreatment blood folate concentrations (P<0.001). After
standardisation to pretreatment blood concentrations of homocysteine of
12 µmol/l and of folate of 12 nmol/l (approximate average
concentrations for Western populations), dietary folic acid reduced
blood homocysteine concentrations by 25% (95% confidence interval
23% to 28%; P<0.001), with similar effects in the range of 0.5-5 mg
folic acid daily. Vitamin B-12 (mean 0.5 mg daily) produced an
additional 7% (3% to 10%) reduction in blood homocysteine. Vitamin
B-6 (mean 16.5 mg daily) did not have a significant additional effect.
Conclusions: Typically in Western populations, daily
supplementation with both 0.5-5 mg folic acid and about 0.5 mg vitamin
B-12 would be expected to reduce blood homocysteine concentrations by
about a quarter to a third (for example, from about 12 µmol/l to 8-9 µmol/l). Large scale randomised trials of such regimens in high risk
populations are now needed to determine whether lowering blood
homocysteine concentrations reduces the risk of vascular disease.
Key messages
© BMJ 1998
T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?
Read all Rapid Responses